Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency and Rigor

By João L. Carapinha

February 23, 2026

AI Literature Review Integration

AI Literature Review Integration is transforming systematic literature reviews (SLRs), as outlined in this preprint. It provides methodological guidance for incorporating artificial intelligence (AI) into SLRs with a human-in-the-loop approach to maintain scientific rigor. AI accelerates resource-intensive stages like screening and data extraction while tackling risks such as bias, hallucinations, and lack of transparency. The core argument is that AI complements human judgment, enabling faster, scalable evidence synthesis aligned with PRISMA and Cochrane standards, without replacing expert oversight.

Tackling SLR Workload Bottlenecks

There are operational challenges in traditional SLRs, which require months of manual effort to screen thousands of records amid exploding scientific output. This leads to extended timelines, workforce strain, and outdated reviews post-publication. AI Literature Review Integration delivers key advantages, including over 50% reductions in completion time across 17 of 25 studies, five- to sixfold decreases in abstract screening duration, and 55%–64% fewer abstracts needing human review, per a pragmatic review. These efficiencies enable scalability for large evidence bases, like sourcing parameters for economic models in health economics and outcomes research (HEOR), while reducing human error in repetitive tasks and improving pattern detection. Vigilant human validation counters AI biases from training data, preserving methodological integrity.

Human Oversight in AI-Driven SLR Stages

The preprint emphasizes human oversight to address AI limitations, offering structured guidance for AI Literature Review Integration across SLR stages, drawn from authors’ experience and literature. It follows the Cochrane Handbook’s process—from research question definition to reporting—via a detailed table. AI prioritizes records for title/abstract screening through relevance ranking refined by human feedback, generates search strings with synonyms and MeSH terms, and extracts structured PICO elements, validated against gold-standard datasets. Rigor uses metrics like precision, recall, F1 score, pilot testing, and inter-reviewer reliability (Cohen’s kappa 0.77–0.88). Tools like RobotReviewer handle risk-of-bias assessments, while NLP-ML platforms aid PRISMA diagrams. Protocols ensure transparency with dual AI-human screening, spot checks, and PRISMA standards.

Reference url

Recent Posts

FDA Approval Lumvoa Therapeutics
FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease

By João L. Carapinha

June 29, 2026

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.
HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...